P. Naud

发表

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

Henry C Kitchener, Bart Spiessens, Frank Struyf, 2007, The Lancet.

Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study

C. Wheeler, S. Garland, X. Castellsagué, 2013, PloS one.

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

Daron G Ferris, Diane M Harper, Gary Dubin, 2004, The Lancet.

Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression models.

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2012, European journal of gynaecological oncology.

Competing-Risks Regression Models in Analysis of Biomarkers as Predictors of High-risk Human Papillomavirus (HPV) Infection Outcomes and Incident CIN in the LAMS Cohort

S. Tatti, S. Syrjänen, K. Syrjänen, 2013, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Up-regulation of lipocalin 2 is associated with high-risk human papillomavirus and grade of cervical lesion at baseline but does not predict outcomes of infections or incident cervical intraepithelial neoplasia.

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2010, American journal of clinical pathology.

Up-regulation of 14-3-3sigma (Stratifin) is associated with high-grade CIN and high-risk human papillomavirus (HPV) at baseline but does not predict outcomes of HR-HPV infections or incident CIN in the LAMS study.

S. Tatti, S. Syrjänen, K. Syrjänen, 2010, American journal of clinical pathology.

Up-regulation of plasminogen activator inhibitor-2 is associated with high-risk HPV and grade of cervical lesion at baseline but does not predict outcomes of high-risk HPV infections or incident CIN.

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2009, American journal of clinical pathology.

Drug addiction is not an independent risk factor for oncogenic human papillomavirus infections or high-grade cervical intraepithelial neoplasia: case-control study nested within the Latin American Screening study cohort

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2008, International journal of STD & AIDS.

Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America: This report refers to partial results from the LAMS (Latin AMerican Screening) study

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2005 .

Cervical Cancer Screening in Porto Alegre, Brazil: Alternative Methods for Detecting Cancer Precursors in a Developing Country

J. Prolla, K. Syrjänen, P. Naud, 2001, Journal of lower genital tract disease.

Conventional Pap Smear and Liquid-Based Cytology as Screening Tools in Low-Resource Settings in Latin America

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2005, Acta Cytologica.

Determinants of Acquisition and Clearance of Human Papillomavirus Infection in Previously Unexposed Young Women

D. Harper, A. Moscicki, E. Franco, 2019, Sexually transmitted diseases.

Optional screening strategies for cervical cancer using standalone tests and their combinations among low- and medium-income populations in Latin America and Eastern Europe

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2010, Journal of medical screening.

Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial.

H. Kitchener, M. Lehtinen, D. Harper, 2012, Gynecologic oncology.

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

D. Lowy, C. Wheeler, S. Wacholder, 2015, The Lancet. Oncology.

Smoking worsens the prognosis of mild abnormalities in cervical cytology

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2009, Acta obstetricia et gynecologica Scandinavica.

Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease.

K. Syrjänen, R. Tekmal, N. Kirma, 2008, Gynecologic oncology.

Efficacy and Tolerability of Thermocoagulation Treatment of High-Grade Cervical Intraepithelial Neoplasia

F. Cidral-filho, P. Naud, A. d’Acampora, 2021, Open Journal of Obstetrics and Gynecology.

Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology

Margherita Branca, Cecília Roteli-Martins, Kari Syrjänen, 2012, Virchows Archiv.

Self-sampling for human papillomavirus (HPV) testing as cervical cancer screening option. Experience from the LAMS study.

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2008, European journal of gynaecological oncology.

Increased Risk of Oncogenic Human Papillomavirus Infections and Incident High-Grade Cervical Intraepithelial Neoplasia Among Smokers: Experience From the Latin American Screening Study

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2009, Sexually transmitted diseases.

Factors predicting intermediate endpoints of cervical cancer and exposure to human papillomavirus (HPV) infections in young women screened as potential targets for prophylactic HPV vaccination in south of Brazil.

K. Syrjänen, P. Naud, L. Hammes, 2006, European journal of obstetrics, gynecology, and reproductive biology.

Effi cacy of a prophylactic adjuvanted bivalent L 1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women : an interim analysis of a phase III double-blind , randomised controlled trial

C. Wheeler, H. Kitchener, M. Lehtinen, 2007 .

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

C. Wheeler, H. Kitchener, M. Lehtinen, 2012, The Lancet. Oncology.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

C. Wheeler, H. Kitchener, M. Lehtinen, 2012, The Lancet. Oncology.

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

B Romanowski, H. Kitchener, M. Lehtinen, 2009, The Lancet.

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine

P. Naud, B. Geeraerts, J. Teixeira, 2014, Human vaccines & immunotherapeutics.

Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial

D. Harper, A. Moscicki, P. Naud, 2016, BMJ Open.

Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

C. Wheeler, H. Kitchener, M. Lehtinen, 2015, Clinical and Vaccine Immunology.

Post Hoc Analysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA

Frank Struyf, Brigitte Colau, Cosette M Wheeler, 2014, Clinical and Vaccine Immunology.

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women.

P. Naud, N. S. Carvalho, J. Teixeira, 2010, Vaccine.

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

C. Wheeler, D. Harper, A. Moscicki, 2009, The Lancet.

Persistent High-Risk Human Papillomavirus Infections and Other End-Point Markers of Progressive Cervical Disease Among Women Prospectively Followed up in the New Independent States of the Former Soviet Union and the Latin American Screening Study Cohorts

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2009, International Journal of Gynecologic Cancer.

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized, controlled trial

C. Wheeler, D. Harper, W. Quint, 2005 .

Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression--clinicopathological correlation.

K. Syrjänen, R. Tekmal, N. Kirma, 2007, Gynecologic oncology.

Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18

C. Wheeler, H. Kitchener, M. Lehtinen, 2012, International journal of cancer.

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine

P. Naud, B. Geeraerts, J. Teixeira, 2012, Human vaccines & immunotherapeutics.

Co-factors of high-risk human papillomavirus infections display unique profiles in incident CIN1, CIN2 and CIN3

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2011, International journal of STD & AIDS.

Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials

S. Wacholder, M. Sherman, M. Schiffman, 2018, The Journal of infectious diseases.

p300 Expression is Related to High-risk Human Papillomavirus Infections and Severity of Cervical Intraepithelial Neoplasia But Not to Viral or Disease Outcomes in a Longitudinal Setting

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Prevalence of Human Papillomavirus Infection and Associated Risk Factors in Young Women in Brazil, Canada, and the United States: A Multicenter Cross-sectional Study

W. Quint, P. Naud, G. Dubin, 2011, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Efficacy of a bivalent L 1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : a randomised controlled trial

Daron G Ferris, Wim Quint, Diane M Harper, 2005 .

Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2009, Virchows Archiv.

Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2005, International Journal of Gynecologic Cancer.

Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial

M. Lehtinen, S. Garland, X. Castellsagué, 2016, International journal of cancer.

Value of the International Federation for Cervical Pathology and Colposcopy (IFCPC) Terminology in Predicting Cervical Disease

K. Syrjänen, P. Naud, E. Passos, 2007, Journal of lower genital tract disease.

Hormonal Contraceptives and the Length of Their Use Are Not Independent Risk Factors for High-Risk HPV Infections or High-Grade CIN

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2010, Gynecologic and Obstetric Investigation.

Efficacy, safety, and acceptability of thermocoagulation for treatment of cervical intraepithelial neoplasia in a hospital setting in Brazil

P. Naud, R. Sankaranarayanan, R. Muwonge, 2016, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine

C. Wheeler, D. Harper, W. Quint, 2007 .

Computer-assisted Immunohistochemical Analysis of Cervical Cancer Biomarkers Using Low-cost and Simple Software

Adhemar Longatto-Filho, João Sabino Cunha-Filho, A. Longatto-Filho, 2007, Applied immunohistochemistry & molecular morphology : AIMM.

Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study.

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2005, Anticancer research.

Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA

C. Wheeler, H. Kitchener, M. Lehtinen, 2014, The Journal of infectious diseases.

Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2006, Journal of medical screening.

Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial

C. Wheeler, M. Lehtinen, S. Garland, 2014, BMC Infectious Diseases.

Longitudinal outcomes of high-risk human papillomavirus (HPV) infections as competing-risks events following cervical HPV test at baseline visit in the NIS-LAMS cohort.

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2012, European journal of gynaecological oncology.

Risk of first cervical HPV infection and precancerous lesions after onset of sexual activity Castellsague

C. Wheeler, F. X. Bosch, M. Lehtinen, 2022 .

Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic HPV-naïve population

C. Wheeler, H. Kitchener, M. Lehtinen, 2009 .

Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease.

K. Syrjänen, R. Tekmal, N. Kirma, 2008, Gynecologic oncology.

H. Kitchener, M. Lehtinen, X. Castellsagué, 2012, The Lancet. Oncology.

H. Kitchener, M. Lehtinen, S. Garland, 2015, Clinical and Vaccine Immunology.

Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study

S. Tatti, A. Longatto-Filho, S. Syrjänen, 2005, International Journal of Gynecologic Cancer.

and persistent infection with non-vaccine oncogenic HPV types using an alternative

D. Harper, S. Garland, P. Naud, 2014 .